Peter McCullough on health: what the evidence says · JRE #1747

What the evidence says 01 / RECORD

McCullough did testify before the U.S. Senate Committee on Homeland Security and Governmental Affairs on November 19, 2020, at a hearing titled "Early Outpatient Treatment: An Essential Part of a COVID-19 Solution," where he argued that early multi-drug outpatient treatment protocols could reduce hospitalization and death. His written testimony submitted to the committee does not contain a specific, sourced 50% (or later 85%) preventable-death figure, and no peer-reviewed study of population-level COVID-19 mortality has produced such an estimate. The early-treatment regimens McCullough promoted centered on repurposed drugs including hydroxychloroquine and ivermectin, but subsequent large randomized controlled trials found no meaningful clinical benefit from these agents: the NIH-funded ACTIV-6 platform trial, published in JAMA in 2022, found ivermectin did not significantly shorten symptom duration or reduce hospitalization or death in outpatients with mild-to-moderate COVID-19 compared with placebo. Because the specific 50%/85% prevented-death figures are not derived from any controlled trial of population-level COVID-19 mortality and rest on treatments not shown to be effective in later RCTs, the claimed percentages are unsupported by the current evidence base, even though the underlying fact that McCullough testified before the Senate on that date is accurate.